Evaluation of drug interaction between cyclosporine and lercanidipine: a descriptive study.

Autor:	Tecen-Yucel K; Department of Clinical Pharmacy, Anadolu University Faculty of Pharmacy, Eskisehir, Turkey kamertecen@anadolu.edu.tr., Bayraktar-Ekincioglu A; Department of Clinical Pharmacy, Hacettepe University Faculty of Pharmacy, Ankara, Turkey., Yıldırım T; Department of Nephrology, Hacettepe University Hospitals, Ankara, Turkey., Demirkan K; Department of Clinical Pharmacy, Hacettepe University Faculty of Pharmacy, Ankara, Turkey., Erdem Y; Department of Nephrology, Hacettepe University Hospitals, Ankara, Turkey.
Jazyk:	angličtina
Zdroj:	European journal of hospital pharmacy : science and practice [Eur J Hosp Pharm] 2024 Oct 25; Vol. 31 (6), pp. 560-563. Date of Electronic Publication: 2024 Oct 25.
DOI:	10.1136/ejhpharm-2023-003757
Abstrakt:	Objectives: Cyclosporine is an immunosuppressive drug with a high potential for drug interactions that is frequently used in renal transplant patients. The purpose of this study was to assess the change in cyclosporine concentration in patients taking cyclosporine and lercanidipine concurrently. Methods: The potential drug interactions in renal transplant patients who received lercanidipine and cyclosporine concurrently in a university hospital between January 2008 and January 2018 were evaluated retrospectively. Patients had renal transplantation from deceased donors or living related donors. The Drug Interaction Probability Scale (DIPS) criteria were used to assess the causality of cyclosporine and lercanidipine drug interaction. Results: The study included six renal transplant patients. The median cyclosporine concentration before lercanidipine use was 325 ng/mL (min-max 101-356) and 592.5 ng/mL (min-max 198-799) thereafter (p=0.028). Serum creatinine and proteinuria levels did not change significantly during lercanidipine treatment (p=0.686 and p=0.116, respectively). According to the DIPS evaluation, cyclosporine and lercanidipine interaction was classified as "possible (score 3)". Conclusions: Concomitant use of cyclosporine and lercanidipine increases the concentration of cyclosporine, which may result in side effects during effective treatment in renal transplant patients. Therefore, cyclosporine concentrations should definitely be monitored while patients are taking lercanidipine. Competing Interests: Competing interests: None declared. (© European Association of Hospital Pharmacists 2024. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu